Research programme: autologous T cell receptor therapies - Zelluna Immunotherapy
Alternative Names: ZI-HXLatest Information Update: 28 Mar 2023
At a glance
- Originator Zelluna Immunotherapy
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Solid-tumours in Norway (Parenteral)
- 04 Feb 2021 Research programme: autologous T cell receptor therapies - Zelluna Immunotherapy is available for licensing as of 24 Sep 2020. zelluna.com/partnering
- 28 Feb 2019 Preclinical trials in Solid tumours in Norway (Parenteral) (Zelluna Immunotherapy pipeline, December 2019)